The PTEN gene encodes a master regulator protein that exerts essential functions both in the cytoplasm and in the nucleus. PTEN is mutated in the germline of both patients with heterogeneous tumor syndromic diseases, categorized as PTEN hamartoma tumor syndrome (PHTS), and a group affected with autism spectrum disorders (ASD). Previous studies have unveiled the functional heterogeneity of PTEN variants found in both patient cohorts, making functional studies necessary to provide mechanistic insights related to their pathogenicity. Here, we have functionally characterized a PTEN missense variant [c.49C>G; p.(Gln17Glu); Q17E] associated to both PHTS and ASD patients. The PTEN Q17E variant displayed partially reduced PIP3-catalytic activity and normal stability in cells, as shown using S. cerevisiae and mammalian cell experimental models. Remarkably, PTEN Q17E accumulated in the nucleus, in a process involving the PTEN N-terminal nuclear localization sequence. The analysis of additional germline-associated PTEN N-terminal variants illustrated the existence of a PTEN N-terminal region whose targeting in disease causes PTEN nuclear accumulation, in parallel with defects in PIP3-catalytic activity in cells. Our findings highlight the frequent occurrence of PTEN gene mutations targeting PTEN N-terminus whose pathogenicity may be related, at least in part, with the retention of PTEN in the nucleus. This could be important for the implementation of precision therapies for patients with alterations in the PTEN pathway.
Introduction
The PTEN gene encodes a phosphatase whose major activity is the dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate (PIP3) to render phosphatidylinositol 4,5-bisphosphate (PIP2). This enzymatic activity counteracts the action of class I phosphatidylinositol 3-kinases (PI3K), thus negatively regulating the PI3K/AKT/mTOR pro-survival signaling pathway [1] [2] [3] . PTEN also dephosphorylates a wide array of proteins, some of which are related with the regulation of cell motility and migration [4] . In addition, PTEN possesses catalysis-independent activities, mainly mediated by protein-protein interactions [5] . Both, catalysis-dependent and -independent activities are associated with specific PTEN subcellular compartmentation. In particular, cytoplasmic localization and transient binding of PTEN to membranes is related with the dephosphorylation of PIP3, whereas PTEN nuclear localization is mostly associated with transcriptional regulation and DNA damage control mediated by protein-protein interactions [6] [7] [8] [9] . The regulated intracellular shuttling of PTEN involves several molecular determinants in the PTEN protein, which include, among others, a cluster of phosphorylatable amino acids at PTEN C-terminal tail and a set of overlapping subcellular localization motifs at PTEN N terminus (NLMs, N-terminal localization motifs) [10] [11] [12] . Conformational changes in the PTEN protein that expose these motifs to targeting or anchoring moieties regulate PTEN catalytic activity and subcellular distribution in cells [8, [13] [14] [15] [16] .
The PTEN gene is the second tumor suppressor, after TP53, in terms of somatic mutation frequency in human tumors. PTEN is also mutated in the germline of patients with syndromic predisposition to several types of cancer, grouped as PHTS (PTEN hamartoma tumor syndrome) [17] . In addition, the PTEN gene is mutated in up to 15% of autism spectrum disroders (ASD) patients with macrocephaly, and other genes directly related with the PI3K/ AKT/mTOR pathway, including the PIK3CA, PIK3R1, AKT1, and AKT3 protooncogenes, have also been found mutated in the germline of patients with tumor predisposition or with megalencephaly-related disorders [18] [19] [20] [21] [22] . This is in line with an important contribution for the effectors of the PI3K/AKT/mTOR pathway not only in tissue oncogenesis, but also in brain growth and development [23, 24] . In ASD patients, PTEN variants generated by missense mutations are prevalent, and although their functional impact in terms of PTEN catalytic activity is variable, many of these variants do not show severe intrinsic impaired catalytic activity but display diminished protein stability [25] [26] [27] . Intriguingly, several missense germline mutations at PTEN have been found on both PHTS and ASD patients, indicating a heterogeneous penetrance for these mutations, which could be due in part to PTEN functional alterations which go beyond its catalytic activity. In this study, we have functionally characterized a PTEN variant found on both PHTS and ASD patients [c.49C>G; p.(Gln17Glu); Q17E]. The PTEN Q17E variant retained most of PTEN stability and catalytic activity, but displayed abnormal subcellular localization, being enriched in the cell nucleus. Further analysis unveiled that disease-associated variants displaying amino acid substitutions at PTEN N-terminus frequently cause both PTEN nuclear accumulation and defects in PTEN catalytic activity in cells. Our findings suggest that misregulated PTEN nuclear accumulation could be related, at least in part, with the pathogenicity of a group of diseaseassociated PTEN variants.
Materials and methods

Cell culture, transfections, plasmids, and mutagenesis
Simian kidney COS-7 cells were grown in DMEM containing high glucose supplemented with 5% heat-inactivated fetal bovine serum (FBS), 1 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Human glioblastoma U87MG cells were grown in DMEM containing high glucose supplemented with 10% heat-inactivated FBS, 1 mM L-glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Cells were grown at 37°C, 5% CO 2 . Cells were transfected by the DEAE-dextran method (COS-7 cells) or using Lipofectamine (ThermoFisher Scientific, USA) (U87MG cells), and processed after 48 h. For experiments of protein stability, cells were treated with 800 μg/ml cycloheximide (Sigma-Aldrich) for 6 h before lysis. The Saccharomyces cerevisiae strain YPH499 (MATa ade2-101 trp1-63 leu2-1 ura3-52 his3-Δ200 lys2-801) was used for heterologous expression of mammalian proteins. YPH499 yeast cells were grown in synthetic complete (SC) medium, containing 0.17% yeast nitrogen base without amino acids, 0.5% ammonium sulfate supplemented with appropriate amino acids and nucleic acid bases, and added 2% glucose (SD), galactose (SG), or raffinose (SR), as required. Yeasts were transformed by standard procedures, and drop growth assays and GFP-AKT1 distribution analyses were performed as described [12, 28, 29] . pRK5 PTEN, pSG5 AKT1, pYES2 PTEN, and YCpLG myc-p110α-CAAX plasmids have been previously described [10, 28] . The pRK5 PTEN-GFP (C-terminal tagging) plasmid was made by PCR and subcloning into pRK5. The PTEN and PTEN-GFP amino acid substitution variants were made by PCR oligonucleotide site-directed mutagenesis as described [30] , and mutations were confirmed by DNA sequencing. Nucleotide and amino acid numbering for PTEN variants correspond to reference sequences from accession numbers NM_000314.4 and NP_000305.3, respectively. Nomenclature of variants is according to ref. [31] . Variants and phenotypes data have been deposited in the LOVD gene variant database (http://www.lovd.nl/3.0/home) [32] , with the following accession IDs: https://databases.lovd.nl/shared/variants/ 0000351723, 0000352569-0000352584, 0000352586-0000352590, and 0000353018.
Immunofluorescence and microscopy techniques PTEN subcellular location in COS-7 cells immunofluorescence was determined by immunofluorescence as previously described, using mouse monoclonal anti-PTEN 425A and fluorescein-conjugated anti-mouse antibody [12, 33] . PTEN-GFP (green fluorescence protein) subcellular location in COS-7 cells was directly visualized by standard fluorescence microscopy. For quantitation of PTEN subcellular distribution, at least 50 positive cells were scored for each experiment. Cells were rated as showing nuclear staining (N), cytoplasmic staining (C), or staining within both the nucleus and the cytoplasm (N/C). Nuclei were identified by DAPI (Sigma-Aldrich, USA) staining. All pictures were taken under a ×20 magnification. Measurement of GFP-AKT1 plasma membrane localization in yeast, as an indirect indicator of cellular PIP3 levels, was performed by fluorescence microscopy, as described [12, 28] . More than 100 cells were examined and scored for each condition or experiment for either cytoplasmic or membrane-associated localization.
Immunoblotting
Whole-cell protein extracts from COS-7 and U87MG cells overexpressing ectopic PTEN variants were prepared by cell lysis in ice-cold M-PER TM lysis buffer (ThermoFisher Scientific) supplemented with PhosSTOP phosphatase inhibitor and cOmplete protease inhibitor cocktails (Roche, Switzerland), followed by centrifugation at 15,200 × g for 10 min and collection of the supernatant. Proteins (50-100 μg) were resolved in 10% SDS-PAGE under reducing conditions and transferred to PVDF membranes. Immunoblotting was performed using antiphospho-Ser473-AKT and anti-AKT (Cell Signaling Technologies, USA), anti-PTEN 6H2.1 (Merck Millipore, USA), or anti-GAPDH (Santa Cruz Biotechnology, USA) antibodies, followed by horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse (Calbiochem, USA) antibodies. For determination of phospho-AKT content and PTEN protein stability, bands were quantified using an Image studio TM software with Odyssey® CLx Imaging System (LI-COR, USA).
Results and discussion
The PTEN Q17E variant targets the PTEN N-terminal localization motifs
The PTEN Q17E mutational variant [c.49C>G; p. (Gln17Glu)] has been reported both in PHTS and ASD patients [34, 35] , suggesting a relevant functional impact on PTEN function. The PTEN residue Gln17 (Q17) is located within the PTEN N-terminal localization motifs (NLMs) of the PTEN PTP domain, which include a PIP2-binding motif (PBM, residues 6-15) [36] , a nuclear localization signal (NLS, residues 8-32) [10] , and a cytoplasmic localization signal (CLS, residues 19-25) [37] . As with other amino acids in this region, Q17 is well conserved among species, although in the fly D. melanogaster a Lys (K) is present in the equivalent position (Fig. 1a) . This suggests that Q17 is important, but not essential, for PTEN function. The PTEN NLMs are surface-exposed, which facilitates their interaction with targeting or regulatory moieties, and they show the same topological orientation with the positively charged TIloop at the PTEN PTP domain, as well as the CBR3-and Cα2-membrane-binding loops at the C2 domain (Fig. 1b) [8, 38, 39] . Together, these observations suggest a role for Q17 in regulation of the function and the subcellular partitioning of PTEN.
The PTEN Q17E variant displays slightly reduced PIP3-phosphatase activity and is stable in cells
We have previously shown that a PTEN Q17A experimental variant [c.(49C>G; 50A>C); p.(Gln17Ala)] slightly affects the PIP3-phosphatase activity of PTEN in a heterologous yeast system without affecting PTEN nuclear/ cytoplasmic distribution [12] . Here, we have analyzed, both in yeast and in mammalian cells transfected with the (Fig. 2a, b ) and in mammalian cells (Fig. 2c) [40] .
The ASD-associated PTEN variants frequently cause destabilization and degradation of the PTEN protein [25, 27] . Next, we analyzed the protein stability of the PTEN Q17E variant in transfected mammalian COS-7 and U87MG cells by measuring protein degradation in the presence of the protein synthesis inhibitor cycloheximide, in comparison with the unstable PTEN D252G variant [c.755A>G; p.(Asp252Gly)] (also found in ASD and PTHS patients) [27] . As shown, PTEN Q17E protein stability was similar to that of PTEN wild type, and higher to that displayed by PTEN D252G (Fig. 3) . Thus, different to other PTEN variants associated to disease (such as Q17P or D252G), that strongly affect PTEN catalysis or protein stability, the PTEN Q17E variant displayed slightly diminished PIP3-phosphatase activity and normal protein stability in cells. Interestingly, the Q17E variant has not been reported up to date in cancer somatic mutation databases, such as COSMIC or cBioPortal (Supplementary  Table 1 , and data not shown). , and the phosphorylation of AKT (as an indirect measurement of PTEN catalytic activity) was monitored by immunoblotting using anti-pAKT (Ser473) antibody. The expression of total AKT, PTEN, and GAPDH (as a loading control) was also monitored using specific antibodies. In the top panels, representative experiments are shown. In the bottom panels, the pAKT/AKT ratio from each condition is shown, after quantification of the bands from at least three independent experiments. Student's t test P values are shown. Note the slight decrease (statistically non-significant) in PTEN Q17E activity when compared with PTEN wild type The PTEN Q17E variant accumulates in the nucleus Next, we assessed the subcellular distribution of PTEN Q17E, in comparison with PTEN wild type, PTEN Q17A, and PTEN Q17P. Immunofluorescence analysis in transfected COS-7 cells revealed that PTEN Q17E, but not PTEN wild type or Q17A, accumulated in the nucleus (Fig. 4a) . Remarkably, the glioma-associated PTEN Q17P variant also displayed increased nuclear accumulation, unveiling a crucial role for the Q17 residue in the control of PTEN nucleus-cytoplasm shuttling. As shown in Fig. 4a , a PTEN K13A experimental variant [c. (37A>G; 38A>C) ; p. (Lys13Ala)] with a non-functional N-terminal NLS [10, 12] , did not show these changes, demonstrating the involvement of the N-terminal NLS in the nuclear accumulation of the PTEN Q17E and Q17P variants. When a PTEN-GFP protein was used to monitor PTEN subcellular localization in transfected COS-7 cells, the nuclear accumulation of PTEN Q17E and Q17P was also observed, and was dependent on the integrity on the N-terminal PTEN NLS as well (Fig. 4b) . This is in agreement with the observation that a PTEN-GFP Q17E variant is modestly accumulated in the nucleus of D. discoideum cells [40] . Mutation of the PTEN catalytic Cys (PTEN C124S variant) had no effect on the subcellular distribution of PTEN Q17E or Q17P, indicating that the nuclear accumulation of these PTEN variants is independent of PTEN catalysis (Fig. 4b) .
Germline-associated variants targeting the PTEN N terminus cause PTEN nuclear accumulation
Next, we analyzed the subcellular localization of the complete set of N-terminal PTEN variants, expanding residues 12-32, found in the germline of PHTS or ASD patients, using PTEN-GFP as the reporter (Supplementary Table 1 ). As shown, nuclear accumulation was prominent on diseaseassociated variants targeting residues 17-26 ( Fig. 5a and Supplementary Table 1 ). This is in agreement with the findings by Denning et al., which proposes the existence of a CLS at this PTEN region [37] . Alternatively, the 17-26 PTEN region could behave as a nuclear exclusion motif, as proposed for regions at the TI-, CBR3-, and Cα2-loops [8, 10] , which hampers the exposure of the overlapping atypical NLS motif at residues 8-32. Interestingly, the PTEN PBM overlaps with the NLS (see Fig. 1a) , and it has been proposed a dynamic and cooperative role for the PBM and N12I  N12T  K13E  R14G  R15S  Y16H  Q17E  D22E  D22G  L23F  L23V  D24G  D24H  D24V  D24Y  L25F  T26I  T26P  Y27C  Y27N  P30L N12I  N12T  K13E  R14G  R15S  Y16H  Q17E  D22E  D22G  L23F  L23V  D24G  D24H  D24V  D24Y  L25F  T26I  T26P  Y27C  Y27N  P30L  I32N Akt in C Akt in PM TI-loop at the PTP domain, as well as the CBR3-and Cα2-loops at the C2 domain, for PTEN plasma membrane binding and activation [38, 41, 42] . Thus, the exposed loop at the N-terminal NLMs PTEN region (Fig. 1b) could work as a PTEN conformational sensor regulating both PTEN subcellular localization and lipid phosphatase activity. In our experiments, the PIP3 in vivo functional analysis showed a partial or total loss-of-function phenotype for most variants at the 17-26 region ( Fig. 5b ; Supplementary Table 1) , suggesting a link between a defective catalytic activity in cells and aberrant nuclear accumulation. Our results argue that mutations affecting PTEN function and targeting the PTEN N-terminal region frequently favor PTEN nuclear accumulation in parallel with decreasing PTEN PIP3-phosphatase activity in cells. This suggests that PTEN nuclear accumulation could be a surrogate marker for loss of PIP3-phosphatase activity in some patients carrying PTEN N-terminal variants. In addition, N-terminal mutated nuclear PTEN could also manifest a dysfunctional role independently of its catalysis, in line with the nuclear retention of PTEN found in some tumors or in cells from some PHTS patients [43, 44] . In this regard, some PHTSassociated PTEN variants that target PTEN at other regions display nuclear accumulation in association with p53 downregulation and increased DNA damage [45, 46] . Further work is required to elucidate the nuclear mechanisms by which N-terminal mutated nuclear PTEN may be causative of PTEN-associated disease. This could shed some light on the variable qualitative penetrance of specific PTEN gene mutations found on both PHTS and ASD patients.
